Dividendos de ESSA Pharma

Dividendo controles de criterios 0/6

ESSA Pharma no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.8%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-US$0.63
Rentabilidad por dividendo prevista a 3 años	n/a

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de EPIX han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de EPIX han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de ESSA Pharma vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de EPIX con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (EPIX)	n/a
Suelo de mercado 25% (US)	1.5%
Techo de mercado 25% (US)	4.8%
Media de la industria (Biotechs)	2.8%
Previsión de analistas en 3 años (EPIX)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de EPIX en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de EPIX en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de EPIX para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que EPIX no ha comunicado ningún pago.

Dividendos de ESSA Pharma

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

New major risk - Revenue and earnings growth

We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate

ESSA Pharma Inc., Annual General Meeting, Mar 06, 2024

New major risk - Revenue and earnings growth

Independent Director recently bought US$135k worth of stock

New major risk - Share price stability

Independent Director recently bought US$420k worth of stock

ESSA Pharma Inc. Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat

ESSA Pharma Inc. Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans

New major risk - Financial position

High number of new directors

Essa Pharma Inc. Appoints Lauren Merendino to Its Board of Directors

Now 21% undervalued after recent price drop

Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)

Now 23% undervalued

Independent Director notifies of intention to sell stock

We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely

ESSA Pharma Inc., Annual General Meeting, Mar 09, 2023

ESSA Pharma Inc. Provides an Update on Its Clinical Collaboration with Janssen

Insufficient new directors

ESSA Pharma Inc. Announces Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat

ESSA Pharma Inc. Appoints Philip Kantoff to its Board of Directors

ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development

ESSA Pharma Inc. Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders

ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting

ESSA Pharma Inc., Annual General Meeting, Mar 09, 2022

ESSA Pharma Inc., Annual General Meeting, Mar 09, 2022

ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients

ESSA Pharma Inc. Enters into Clinical Collaboration and Supply Agreement with Astellas Pharma Inc. to Evaluate Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma Inc. has completed a Follow-on Equity Offering in the amount of $130.434786 million.

ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium

ESSA Pharma: Update Including Clinical Collaboration Agreement With Janssen

ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma and Janssen to test combo treatments in prostate cancer setting

ESSA Pharma EPS beats by $0.02

ESSA Pharma Inc. Announces Voluntary Delisting from the TSX-V

New 90-day low: US$6.10

Independent Chairman of the Board recently bought US$37k worth of stock

Essa Pharma Inc. Announces the Presentation of Data of ESSA's Clinical Candidate, EPI-7386, at the ESMO Virtual Congress 2020

New 90-day high - US$7.64

Independent Director recently bought US$551k worth of stock

New 90-day high - US$7.06

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Descubre empresas que pagan buenos dividendos